Detalles de la búsqueda
1.
Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
Diabetes Obes Metab
; 26(7): 2722-2731, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38618987
2.
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Int J Mol Sci
; 23(14)2022 Jul 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35887308
3.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Diabetes Obes Metab
; 23(4): 886-896, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33319454
4.
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
Diabetes Obes Metab
; 23(7): 1505-1517, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33625777
5.
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
Metabolism
; 140: 155396, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36592688
6.
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.
Nat Metab
; 5(12): 2086-2093, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38066113
7.
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
Ther Innov Regul Sci
; 56(5): 785-794, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35699910
8.
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism.
Mol Metab
; 66: 101620, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36280113
9.
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
Clin J Am Soc Nephrol
; 17(5): 643-654, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35483733
10.
Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.
Diabetes Care
; 44(6): 1334-1343, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33858855
11.
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol
; 9(9): 586-594, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302745
12.
A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?
Int Rev Neurobiol
; 155: 113-140, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854852
13.
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
J Clin Endocrinol Metab
; 104(1): 193-201, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30137410
14.
MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
Eur J Endocrinol
; 178(4): R113-R125, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29371333
15.
Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.
Lancet Diabetes Endocrinol
; 10(2): 98-99, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921753
16.
Erratum. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. Diabetes Care 2021;44:1334-1343.
Diabetes Care
; 45(5): 1297, 2022 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35239964
17.
Resultados
1 -
18
de 18
1
Próxima >
>>